Marktanalyse - Globoid Cell Leukodystrophy (Krabbe Disease) - Pipeline Review, H2 2016

Global Markets Direct
12.2016
45 Seiten

 
Typ:
Marktanalyse
Verfüg­barkeit:
verfügbar
Regionen/­Länder:
  • Europa
  • Asien / Pazifik
  • Mittlerer Osten / Afrika
  • Nordamerika / USA
  • Australien
  • Mittel- / Südamerika
Sprache:
Englisch

Bitte wählen Sie ein Lieferformat und klicken Sie unten auf einen Bestellbutton:

PDF-Datei per E-Mail, Single User Price, versandkostenfrei
PDF-Datei per E-Mail, Site License Price**, versandkostenfrei
PDF-Datei per E-Mail, Enterprisewide Price (Global Site License)***, versandkostenfrei


Hinweise: **The report can be shared by users within one office (one geographical location) ***Across Geographical locations (by the purchasing company only)

Globoid Cell Leukodystrophy (Krabbe Disease) - Pipeline Review, H2 2016


Summary


Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Globoid Cell Leukodystrophy (Krabbe Disease) - Pipeline Review, H2 2016, provides an overview of the Globoid Cell Leukodystrophy (Krabbe Disease) (Central Nervous System) pipeline landscape.

Krabbe disease also called globoid cell leukodystrophy is a degenerative disorder caused by the deficiency of an enzyme called galactosylceramidase. This enzyme deficiency impairs the growth and maintenance of myelin. Symptoms include seizures, Muscle spasms, Loss of head control, vomiting, fevers, irritability and excessive crying. Risk factors include family history. Treatment focuses on managing symptoms (anticonvulsant, muscle relaxer) and providing supportive care.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Globoid Cell Leukodystrophy (Krabbe Disease) - Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Globoid Cell Leukodystrophy (Krabbe Disease) (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Globoid Cell Leukodystrophy (Krabbe Disease) (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Globoid Cell Leukodystrophy (Krabbe Disease) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase I and Preclinical stages are 2 and 2 respectively. Similarly, the Universities portfolio in Phase I and Preclinical stages comprises 1 and 1 molecules, respectively.Globoid Cell Leukodystrophy (Krabbe Disease).

Globoid Cell Leukodystrophy (Krabbe Disease) (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.


Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Globoid Cell Leukodystrophy (Krabbe Disease) (Central Nervous System).
- The pipeline guide reviews pipeline therapeutics for Globoid Cell Leukodystrophy (Krabbe Disease) (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Globoid Cell Leukodystrophy (Krabbe Disease) (Central Nervous System) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Globoid Cell Leukodystrophy (Krabbe Disease) (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Globoid Cell Leukodystrophy (Krabbe Disease) (Central Nervous System)


Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Globoid Cell Leukodystrophy (Krabbe Disease) (Central Nervous System).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Globoid Cell Leukodystrophy (Krabbe Disease) (Central Nervous System) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents

Table of Contents 2

List of Tables 4

List of Figures 4

Introduction 5

Global Markets Direct Report Coverage 5

Globoid Cell Leukodystrophy (Krabbe Disease) Overview 6

Therapeutics Development 7

Pipeline Products for Globoid Cell Leukodystrophy (Krabbe Disease) - Overview 7

Pipeline Products for Globoid Cell Leukodystrophy (Krabbe Disease) - Comparative Analysis 8

Globoid Cell Leukodystrophy (Krabbe Disease) - Therapeutics under Development by Companies 9

Globoid Cell Leukodystrophy (Krabbe Disease) - Therapeutics under Investigation by Universities/Institutes 10

Globoid Cell Leukodystrophy (Krabbe Disease) - Pipeline Products Glance 11

Clinical Stage Products 11

Early Stage Products 12

Globoid Cell Leukodystrophy (Krabbe Disease) - Products under Development by Companies 13

Globoid Cell Leukodystrophy (Krabbe Disease) - Products under Investigation by Universities/Institutes 14

Globoid Cell Leukodystrophy (Krabbe Disease) - Companies Involved in Therapeutics Development 15

Commence Bio Inc 15

Kyorin Pharmaceutical Co Ltd 16

Novartis AG 17

Nuo Therapeutics Inc 18

Globoid Cell Leukodystrophy (Krabbe Disease) - Therapeutics Assessment 19

Assessment by Monotherapy Products 19

Assessment by Target 20

Assessment by Mechanism of Action 22

Assessment by Route of Administration 24

Assessment by Molecule Type 26

Drug Profiles 28

ALD-601 - Drug Profile 28

Product Description 28

Mechanism Of Action 28

R&D Progress 28

CMB-200 - Drug Profile 29

Product Description 29

Mechanism Of Action 29

R&D Progress 29

DUOC-01 - Drug Profile 30

Product Description 30

Mechanism Of Action 30

R&D Progress 30

HSC-835 - Drug Profile 31

Product Description 31

Mechanism Of Action 31

R&D Progress 31

ibudilast - Drug Profile 32

Product Description 32

Mechanism Of Action 32

R&D Progress 32

Stem Cell Therapy for Globoid Cell Leukodystrophy - Drug Profile 40

Product Description 40

Mechanism Of Action 40

R&D Progress 40

Globoid Cell Leukodystrophy (Krabbe Disease) - Dormant Projects 41

Globoid Cell Leukodystrophy (Krabbe Disease) - Discontinued Products 42

Globoid Cell Leukodystrophy (Krabbe Disease) - Product Development Milestones 43

Featured News & Press Releases 43

Jan 18, 2016: FDA Grants Rare Pediatric Disease Designation to MediciNova’s MN-166 (ibudilast) for the Treatment of Krabbe Disease 43

Jun 03, 2015: MediciNova Announces FDA Granted Orphan Drug Designation to MN-166 (ibudilast) for Krabbe Disease 43

Appendix 44

Methodology 44

Coverage 44

Secondary Research 44

Primary Research 44

Expert Panel Validation 44

Contact Us 44

Disclaimer 45





List of Tables

Number of Products under Development for Globoid Cell Leukodystrophy (Krabbe Disease), H2 2016 7

Number of Products under Development for Globoid Cell Leukodystrophy (Krabbe Disease) - Comparative Analysis, H2 2016 8

Number of Products under Development by Companies, H2 2016 9

Number of Products under Investigation by Universities/Institutes, H2 2016 10

Comparative Analysis by Clinical Stage Development, H2 2016 11

Comparative Analysis by Early Stage Development, H2 2016 12

Products under Development by Companies, H2 2016 13

Products under Investigation by Universities/Institutes, H2 2016 14

Globoid Cell Leukodystrophy (Krabbe Disease) - Pipeline by Commence Bio Inc, H2 2016 15

Globoid Cell Leukodystrophy (Krabbe Disease) - Pipeline by Kyorin Pharmaceutical Co Ltd, H2 2016 16

Globoid Cell Leukodystrophy (Krabbe Disease) - Pipeline by Novartis AG, H2 2016 17

Globoid Cell Leukodystrophy (Krabbe Disease) - Pipeline by Nuo Therapeutics Inc, H2 2016 18

Assessment by Monotherapy Products, H2 2016 19

Number of Products by Stage and Target, H2 2016 21

Number of Products by Stage and Mechanism of Action, H2 2016 23

Number of Products by Stage and Route of Administration, H2 2016 25

Number of Products by Stage and Molecule Type, H2 2016 27

Globoid Cell Leukodystrophy (Krabbe Disease) - Dormant Projects, H2 2016 41

Globoid Cell Leukodystrophy (Krabbe Disease) - Discontinued Products, H2 2016 42





List of Figures

Number of Products under Development for Globoid Cell Leukodystrophy (Krabbe Disease), H2 2016 7

Number of Products under Development for Globoid Cell Leukodystrophy (Krabbe Disease) - Comparative Analysis, H2 2016 8

Number of Products under Development by Companies, H2 2016 9

Number of Products under Investigation by Universities/Institutes, H2 2016 10

Comparative Analysis by Clinical Stage Development, H2 2016 11

Comparative Analysis by Early Stage Products, H2 2016 12

Assessment by Monotherapy Products, H2 2016 19

Number of Products by Targets, H2 2016 20

Number of Products by Stage and Targets, H2 2016 20

Number of Products by Mechanism of Actions, H2 2016 22

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016 22

Number of Products by Routes of Administration, H2 2016 24

Number of Products by Stage and Routes of Administration, H2 2016 24

Number of Products by Molecule Types, H2 2016 26

Number of Products by Stage and Molecule Types, H2 2016 26

* Alle Preise sind netto ausgewiesen. In Abhängigkeit von Ihrer Rechnungsanschrift ist hierauf noch USt. zu entrichten (Deutschland z.Z. 19%). Unser Angebot richtet sich ausschließlich an Unternehmen, Gewerbetreibende und Freiberufler.

 

Über marktforschung.de

Branchenwissen an zentraler Stelle bündeln und abrufbar machen – das ist das Hauptanliegen von marktforschung.de. Unser breites Informationsangebot rund um die Marktforschung richtet sich sowohl an Marktforschungsinstitute, Felddienstleister, Panelbetreiber und Herausgeber von Studien, Marktdaten sowie Marktanalysen als auch an deren Kunden aus Industrie, Handel und Dienstleistungsgewerbe.

facebook twitter google plus